Patents by Inventor Christopher O'Sullivan

Christopher O'Sullivan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160362661
    Abstract: The invention provides methods for depleting extraneous phenotypes from a mixed population of cells comprising the in vitro differentiated progeny of primate pluripotent stem cells, The invention also provides cell populations enriched for target cell populations which are the differentiated in vitro progeny of primate pluripotent stem cells.
    Type: Application
    Filed: January 11, 2016
    Publication date: December 15, 2016
    Inventors: Christopher O'Sullivan, Kevin Nishimoto, Anita Reddy
  • Publication number: 20140329314
    Abstract: The invention provides methods for depleting extraneous phenotypes from a mixed population of cells comprising the in vitro differentiated progeny of primate pluripotent stem cells, The invention also provides cell populations enriched for target cell populations which are the differentiated in vitro progeny of primate pluripotent stem cells.
    Type: Application
    Filed: March 28, 2012
    Publication date: November 6, 2014
    Inventors: Christopher O'Sullivan, Kevin Nishimoto, Anita Reddy
  • Publication number: 20100112003
    Abstract: A strain of Bifidobacterium isolated from resected and washed human gastrointestinal tract is significantly immunomodulatory following oral consumption in humans. The strain is useful in the prophylaxis and/or treatment of undesirable inflammatory activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer.
    Type: Application
    Filed: June 5, 2009
    Publication date: May 6, 2010
    Inventors: John Kevin Collins, Gerald Christopher O'Sullivan, Liam O'Mahony, Fergus Shanahan
  • Publication number: 20080311080
    Abstract: A strain of Bifidobacterium isolated from resected and washed human gastrointestinal tract is significantly immunomodulatory following oral consumption in humans. The strain is useful in the prophylaxis and/or treatment of undesirable inflammatory activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer.
    Type: Application
    Filed: May 19, 2008
    Publication date: December 18, 2008
    Applicants: University College Cork - National University of Ireland, Cork
    Inventors: John Kevin Collins, Gerald Christopher O'Sullivan, Liam O'Mahony, Fergus Shanahan
  • Patent number: 7390519
    Abstract: A Lactobacillus salivarius strain, AH102, AH103, AH105, AH109 or AH110 or mutants or variants thereof are useful in the prophylaxis and/or treatment of inflammatory activity especially undesirable gastrointestinal inflammatory activity, such as inflammatory bowel disease or irritable bowel syndrome.
    Type: Grant
    Filed: April 14, 2005
    Date of Patent: June 24, 2008
    Assignee: Alimentary Health Limited
    Inventors: John Kevin Collins, Gerald Christopher O'Sullivan, Liam O'Mahony, Fergus Shanahan, Barry Kiely
  • Patent number: 7195906
    Abstract: A strain of Bifidobacterium isolated from resected and washed human gastrointestinal tract is significantly immunomodulatory following oral consumption in humans. The strain is useful in the prophylaxis and/or treatment of undesirable inflammatroy activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer.
    Type: Grant
    Filed: February 23, 2004
    Date of Patent: March 27, 2007
    Assignees: Enterprise Ireland (Trading as BioResearch Ireland), University College Cork--National University of Ireland
    Inventors: John Kevin Collins, Gerald Christopher O'Sullivan, Liam O'Mahony, Fergus Shanahan
  • Patent number: 7186545
    Abstract: A strain of Lactobacillus salivarius isolated from resected and washed human gastrointestinal tract inhibits a broad range of Gram positive and Gram negative microorganisms and secretes a product having antimicrobial activity into a cell-free supernatant. The activity is produced only by, growing cells and is destroyed by proteinase K and pronase E, the inhibitory properties of the strain and its secretory products being maintained in the presence of physiological concentrations of human bile and human gastric juice. The strain exhibits a broad-spectrum of activity against bacteria including Listeria, Staphylococcus, including methocillin resistant St. aureus (MRSA), and Bacillus, but does not inhibit many closely related lactobacilli. An antimicrobial agent is obtained from the strain which has bacteriocin-like properties.
    Type: Grant
    Filed: June 26, 2003
    Date of Patent: March 6, 2007
    Assignees: Enterprise Ireland, University College Cork - National University of Ireland
    Inventors: John Kevin Collins, Gerald Christopher O'Sullivan, Gerardine Mary Thornton, Marian Mary Geraldine O'Sullivan
  • Patent number: 6872411
    Abstract: A process for the manufacture of a probiotic cheese, such as Cheddar cheese, comprises adding a 0.0-5.5% inoculum of a strain of Lactobacillus paracasei, which is non-pathogenic, acid and bile tolerant and adherent to human epithelial cells, as a starter adjunct to cheese milk, said L. paracasei strain being capable of growing during the ripening phase to a level of 107 cfu/g or greater. The L. paracasei strains are found to grow and proliferate to high cell numbers (in excess of 108 cfu/g) in the cheese over eight months of ripening, even when added at a relatively low inoculum. The presence of the L. paracasei strains is found to have negligible effects on cheese composition, flavor and aroma.
    Type: Grant
    Filed: May 26, 1999
    Date of Patent: March 29, 2005
    Assignees: Enterprise Ireland, Teagasc, The Agriculture and Food Development Authority
    Inventors: Reynolds Paul Ross, Gerald Francis Fitzgerald, John Kevin Collins, Gerald Christopher O'Sullivan, Catherine Gerardine Stanton
  • Publication number: 20040214304
    Abstract: A strain of Lactobacillus salivarius isolated from resected and washed human gastrointestinal tract inhibits a broad range of Gram positive and Gram negative microorganisms and secretes a product having antimicrobial activity into a cell-free supernatant. The activity is produced only by, growing cells and is destroyed by proteinase K and pronase E, the inhibitory properties of the strain and its secretory products being maintained in the presence of physiological concentrations of human bile and human gastric juice. The strain exhibits a broad-spectrum of activity against bacteria including Listeria, Staphylococcus, including methocillin resistant St. aureus (MRSA), and Bacillus, but does not inhibit many closely related lactobacilli. An antirmicrobial agent is obtained from the strain which has bacteriocin-like properties.
    Type: Application
    Filed: June 26, 2003
    Publication date: October 28, 2004
    Applicant: Enterprise Ireland and University College Cork-National University of Ireland, Cork
    Inventors: John Kevin Collins, Gerald Christopher O'Sullivan, Gerardine Mary Thornton, Marian Mary Geraldine O'Sullivan
  • Publication number: 20040038379
    Abstract: A strain of Lactobacillus salivarius isolated from resected and washed human gastrointestinal tract inhibits a broad range of Gram positive and Gram negative microorganisms and secretes a product having antimicrobial activity into a cell-free supernatant. The activity is produced only by growing cells and is destroyed by proteinase K and pronase E, the inhibitory properties of the strain and its secretory products being maintained in the presence of physiological concentrations of human bile and human gastric juice. The strain exhibits a broad-spectrum of activity against bacteria including Listeria, Staphylococcus, including methocillin resistant St. aureus (MRSA), and Bacillus, but does not inhibit many closely related lactobacilli. An antimicrobial agent is obtained from the strain which has bacteriocin-like properties.
    Type: Application
    Filed: June 26, 2003
    Publication date: February 26, 2004
    Applicants: Enterprise Ireland and University College Cork -, National University of Ireland, Cork
    Inventors: John Kevin Collins, Gerald Christopher O'Sullivan, Gerardine Mary Thornton, Marian Mary Geraldine O'Sullivan
  • Publication number: 20030215467
    Abstract: A strain of Bifidobacterium isolated from resected and washed human gastrointestinal tract is significantly immunomodulatory following oral consumption in humans. The strain is useful in the prophylaxis and/or treatment of undesirable inflammatroy activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer.
    Type: Application
    Filed: March 17, 2003
    Publication date: November 20, 2003
    Applicant: Enterprise Ireland (Trading as Bioresearch Ireland and National University of Ireland, Cork.
    Inventors: John Kevin Collins, Gerald Christopher O'Sullivan, Liam O'Mahony, Fergus Shanahan
  • Publication number: 20030170217
    Abstract: A strain of Bifidobacterium isolated from resected and washed human gastrointestinal tract is significantly immunomodulatory following oral consumption in humans. The strain is useful in the prophylaxis and/or treatment of undesirable inflammatroy activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer.
    Type: Application
    Filed: March 3, 2003
    Publication date: September 11, 2003
    Applicant: Enterprise Ireland (Trading as Bioresearch Ireland and National University of Ireland, Cork.
    Inventors: John Kevin Collins, Gerald Christopher O'Sullivan, Liam O'Mahony, Fergus Shanahan
  • Publication number: 20030166257
    Abstract: Lactobacillus salivarius is useful in the prophylaxis or treatment of undesirable inflammatory activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer. The Lactobacillus salivarius is of human origin isolated from resected and washed human gastrointestinal tract. One such strain is UCC 118 described in WO-A-9835014.
    Type: Application
    Filed: September 12, 2002
    Publication date: September 4, 2003
    Applicant: Enterprise Ireland
    Inventors: John Kevin Collins, Gerald Christopher O'Sullivan, Liam O'Mahony, Fergus Shanahan
  • Publication number: 20030113306
    Abstract: A Lactobacillus casei strain or a mutant or variant thereof isolated from resected and washed human gastrointestinal tract is significantly immunomodulatory following oral consumption in humans. In particular a Lactobacillus casei strain, AH101, AH104, AH111, AH112 or AH113 or mutants or variants are thereof are useful in the prophylaxis and/or treatment of inflammatory activity especially undesirable gastrointestinal inflammatory activity, such as inflammatory bowel disease or irritable bowel syndrome.
    Type: Application
    Filed: July 25, 2002
    Publication date: June 19, 2003
    Inventors: John Kevin Collins, Gerald Christopher O'sullivan, Liam O'Mahony, Fergus Shanahan, Barry Kiely
  • Publication number: 20030091549
    Abstract: A Lactobacillus salivarius strain, AH102, AH103, AH105, AH109 or AH110 or mutants or variants thereof are useful in the prophylaxis and/or treatment of inflammatory activity especially undesirable gastrointestinal inflammatory activity, such as inflammatory bowel disease or irritable bowel syndrome.
    Type: Application
    Filed: July 26, 2002
    Publication date: May 15, 2003
    Inventors: John Kevin Collins, Gerald Christopher O'Sullivan, Liam O'Mahony, Fergus Shanahan, Barry Kiely
  • Publication number: 20030092163
    Abstract: A Bifidobacterium strain, AH208, AH209, AH210, AH211, AH212 or AH214 or mutants or variants thereof are useful in the prophylaxis and/or treatment of inflammatory activity especially undesirable gastrointestinal inflammatory activity, such as inflammatory bowel disease or irritable bowel syndrome.
    Type: Application
    Filed: July 25, 2002
    Publication date: May 15, 2003
    Inventors: John Kevin Collins, Gerald Christopher O'Sullivan, Liam O'Mahony, Fergus Shanahan, Barry Kiely
  • Publication number: 20020006432
    Abstract: A strain of Bifidobacterium isolated from resected and washed human gastrointestinal tract is significantly immunomodulatory following oral consumption in humans. The strain is useful in the prophylaxis and/or treatment of undesirable inflammatroy activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer.
    Type: Application
    Filed: July 13, 2001
    Publication date: January 17, 2002
    Inventors: John Kevin Collins, Gerald Christopher O'Sullivan, Liam O'Mahony, Fergus Shanahan
  • Patent number: 5912184
    Abstract: An enclosure provided with an air supply system, an exhaust system, and controls for manipulating the flow, temperature, dewpoint and relative humidity of the air within the enclosure are disclosed. The present invention aims to achieve with these components a system for containing chemical contaminants created during processing of silicon wafers during the chemical/mechanical, polishing/planarization processes involved in creating those wafers. The system prevents drying of the slurry used to process wafers by controlling the relative humidity within the enclosure via a humidifier, sensors and a controller that dynamically reacts to changes within the enclosure atmosphere. Preventing slurry drying is critical to maintaining high wafer throughput by reducing gouging and scraping of wafers and also by reducing equipment down time needed to clean dried slurry.
    Type: Grant
    Filed: June 28, 1997
    Date of Patent: June 15, 1999
    Assignee: Intelligent Enclosures Corporation
    Inventor: Christopher O'Sullivan Young
  • Patent number: 5689057
    Abstract: Crater shaped bumps are made on a calibration disk which can be used for calibrating a PZT slider, the PZT slider in turn being used for detecting predetermined asperities on a production run magnetic disk. The crater shaped bumps emulate predetermined asperities of production run magnetic disks and especially asperities which are undesirable and would cause the production run disk to be discarded after testing by the PZT slider. Crater shaped bumps which emulate undesirable asperities on current production runs of magnetic disks have a diameter in the range of 10 to 25 .mu.m and a peripheral ridge with a height h.sub.r above a nominal surface of the calibration disk in the range of 75 to 120 nm. Close tolerance crater shaped bumps with this configuration can be made by impinging two or more pulses of laser energy on the same location of a calibration disk. By increasing the number of pulses the height of the peripheral ridge progressively increases.
    Type: Grant
    Filed: February 27, 1996
    Date of Patent: November 18, 1997
    Assignee: International Business Machines Corporation
    Inventors: Peter Michael Baumgart, Karl A. Flechsig, Michael Franklin Lee, Wing P. Leung, Ullal Vasant Nayak, Thao Anh Nguyen, Timothy Christopher O'Sullivan, Andrew Ching Tam
  • Patent number: D1027901
    Type: Grant
    Filed: August 15, 2022
    Date of Patent: May 21, 2024
    Assignee: LOGITECH EUROPE S.A.
    Inventors: Vadim Kogan, Damien O'Sullivan, Doug Ebert, David Muñiz, Nicholas Anthony Ross, Kevin Alan Clarridge, Kari Lee Erkkila, Christopher Matthew Krako, Elle Suzanne Stapleton, Jesse Richard Peck